Inspire Medical Systems, which sells an implanted device for treating obstructive sleep apnea, raised $108 million by offering 6.75 million shares at $16, the high end of the range of $14 to $16. It had previously filed to offer 5.0 million shares at the same range. Inspire Medical Systems plans to list on the NYSE under the symbol INSP. BofA Merrill Lynch and Goldman Sachs acted as lead managers on the deal.
The article Inspire Medical Systems prices upsized $108 million IPO at $16 high end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.